Cargando…

Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?

[Image: see text] Thiazoles exhibit a wide range of biological activities and therefore represent useful and attractive building blocks. To evaluate their usefulness and pinpoint their liabilities in fragment screening campaigns, we assembled a focused library of 49 fragment-sized thiazoles and thia...

Descripción completa

Detalles Bibliográficos
Autores principales: Proj, Matic, Hrast, Martina, Knez, Damijan, Bozovičar, Krištof, Grabrijan, Katarina, Meden, Anže, Gobec, Stanislav, Frlan, Rok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743419/
https://www.ncbi.nlm.nih.gov/pubmed/36518695
http://dx.doi.org/10.1021/acsmedchemlett.2c00429
_version_ 1784848722901860352
author Proj, Matic
Hrast, Martina
Knez, Damijan
Bozovičar, Krištof
Grabrijan, Katarina
Meden, Anže
Gobec, Stanislav
Frlan, Rok
author_facet Proj, Matic
Hrast, Martina
Knez, Damijan
Bozovičar, Krištof
Grabrijan, Katarina
Meden, Anže
Gobec, Stanislav
Frlan, Rok
author_sort Proj, Matic
collection PubMed
description [Image: see text] Thiazoles exhibit a wide range of biological activities and therefore represent useful and attractive building blocks. To evaluate their usefulness and pinpoint their liabilities in fragment screening campaigns, we assembled a focused library of 49 fragment-sized thiazoles and thiadiazoles with various substituents, namely amines, bromides, carboxylic acids, and nitriles. The library was profiled in a cascade of biochemical inhibition assays, redox activity, thiol reactivity, and stability assays. Our study indicates that when thiazole derivatives are identified as screening hits, their reactivity should be carefully addressed and correlated with specific on-target engagement. Importantly, nonspecific inhibition should be excluded using experimental approaches and in silico predictions. To help with validation of hits identified in fragment screening campaigns, we can apply our high-throughput profiling workflow to focus on the most tractable compounds with a clear mechanism of action.
format Online
Article
Text
id pubmed-9743419
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-97434192022-12-13 Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? Proj, Matic Hrast, Martina Knez, Damijan Bozovičar, Krištof Grabrijan, Katarina Meden, Anže Gobec, Stanislav Frlan, Rok ACS Med Chem Lett [Image: see text] Thiazoles exhibit a wide range of biological activities and therefore represent useful and attractive building blocks. To evaluate their usefulness and pinpoint their liabilities in fragment screening campaigns, we assembled a focused library of 49 fragment-sized thiazoles and thiadiazoles with various substituents, namely amines, bromides, carboxylic acids, and nitriles. The library was profiled in a cascade of biochemical inhibition assays, redox activity, thiol reactivity, and stability assays. Our study indicates that when thiazole derivatives are identified as screening hits, their reactivity should be carefully addressed and correlated with specific on-target engagement. Importantly, nonspecific inhibition should be excluded using experimental approaches and in silico predictions. To help with validation of hits identified in fragment screening campaigns, we can apply our high-throughput profiling workflow to focus on the most tractable compounds with a clear mechanism of action. American Chemical Society 2022-11-03 /pmc/articles/PMC9743419/ /pubmed/36518695 http://dx.doi.org/10.1021/acsmedchemlett.2c00429 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Proj, Matic
Hrast, Martina
Knez, Damijan
Bozovičar, Krištof
Grabrijan, Katarina
Meden, Anže
Gobec, Stanislav
Frlan, Rok
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
title Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
title_full Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
title_fullStr Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
title_full_unstemmed Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
title_short Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
title_sort fragment-sized thiazoles in fragment-based drug discovery campaigns: friend or foe?
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743419/
https://www.ncbi.nlm.nih.gov/pubmed/36518695
http://dx.doi.org/10.1021/acsmedchemlett.2c00429
work_keys_str_mv AT projmatic fragmentsizedthiazolesinfragmentbaseddrugdiscoverycampaignsfriendorfoe
AT hrastmartina fragmentsizedthiazolesinfragmentbaseddrugdiscoverycampaignsfriendorfoe
AT knezdamijan fragmentsizedthiazolesinfragmentbaseddrugdiscoverycampaignsfriendorfoe
AT bozovicarkristof fragmentsizedthiazolesinfragmentbaseddrugdiscoverycampaignsfriendorfoe
AT grabrijankatarina fragmentsizedthiazolesinfragmentbaseddrugdiscoverycampaignsfriendorfoe
AT medenanze fragmentsizedthiazolesinfragmentbaseddrugdiscoverycampaignsfriendorfoe
AT gobecstanislav fragmentsizedthiazolesinfragmentbaseddrugdiscoverycampaignsfriendorfoe
AT frlanrok fragmentsizedthiazolesinfragmentbaseddrugdiscoverycampaignsfriendorfoe